CN108112997B - A health food composition - Google Patents
A health food composition Download PDFInfo
- Publication number
- CN108112997B CN108112997B CN201711365869.6A CN201711365869A CN108112997B CN 108112997 B CN108112997 B CN 108112997B CN 201711365869 A CN201711365869 A CN 201711365869A CN 108112997 B CN108112997 B CN 108112997B
- Authority
- CN
- China
- Prior art keywords
- collagen
- parts
- pine bark
- health food
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 235000013402 health food Nutrition 0.000 title claims abstract description 11
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims abstract description 22
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims abstract description 22
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims abstract description 22
- 102000000503 Collagen Type II Human genes 0.000 claims abstract description 20
- 108010041390 Collagen Type II Proteins 0.000 claims abstract description 20
- 229940106587 pine bark extract Drugs 0.000 claims abstract description 20
- 235000020741 pine bark extract Nutrition 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 210000000845 cartilage Anatomy 0.000 claims abstract description 16
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 8
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims abstract description 4
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 4
- 235000015487 sulforaphane Nutrition 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000006187 pill Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 241000287828 Gallus gallus Species 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010204 pine bark Nutrition 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000454 talc Substances 0.000 claims 1
- 229910052623 talc Inorganic materials 0.000 claims 1
- 235000012222 talc Nutrition 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 abstract description 12
- 206010007710 Cartilage injury Diseases 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 210000001188 articular cartilage Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 229940088598 enzyme Drugs 0.000 abstract description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 6
- 229920002674 hyaluronan Polymers 0.000 abstract description 6
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 6
- 230000006378 damage Effects 0.000 abstract description 4
- 230000007850 degeneration Effects 0.000 abstract description 4
- 102000029816 Collagenase Human genes 0.000 abstract description 3
- 108060005980 Collagenase Proteins 0.000 abstract description 3
- 108010014258 Elastin Proteins 0.000 abstract description 3
- 102000016942 Elastin Human genes 0.000 abstract description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 abstract description 3
- 102000001974 Hyaluronidases Human genes 0.000 abstract description 3
- 102000016387 Pancreatic elastase Human genes 0.000 abstract description 3
- 108010067372 Pancreatic elastase Proteins 0.000 abstract description 3
- 210000001612 chondrocyte Anatomy 0.000 abstract description 3
- 229960002424 collagenase Drugs 0.000 abstract description 3
- 239000000084 colloidal system Substances 0.000 abstract description 3
- 229920002549 elastin Polymers 0.000 abstract description 3
- 229960002773 hyaluronidase Drugs 0.000 abstract description 3
- 210000003097 mucus Anatomy 0.000 abstract description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 abstract description 2
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 abstract description 2
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 238000013329 compounding Methods 0.000 abstract description 2
- 239000012530 fluid Substances 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 abstract description 2
- 229920002414 procyanidin Polymers 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 230000000593 degrading effect Effects 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 238000007873 sieving Methods 0.000 description 5
- 239000007779 soft material Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000233062 Gymnopus androsaceus Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 241000133134 Saussurea Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- -1 drying Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a health food composition for preventing and treating articular cartilage damage, which is prepared by compounding ossein, hydrolyzed type II collagen, broccoli extract and pine bark extract according to a specific proportion, wherein the ossein can increase the colloid and mucus of joints and accelerate the repair and survival of cartilage tissues and joint fluid; hydrolysis of type II collagen helps to combat chondroprotein degrading enzymes, reconstituting destroyed chondrocytes; sulforaphane in broccoli extract slows down the progression of cartilage damage by preventing the action of various enzymes that cause joint degeneration in osteoarthritis; the pine bark extract contains rich procyanidin, and has obvious inhibition effect on collagenase, elastase, hyaluronidase, etc., thereby reducing the damage effect of these enzymes on collagen, elastin, hyaluronic acid, etc.
Description
Technical Field
The invention relates to a health-care food composition, in particular to a health-care food composition with the function of preventing and treating articular cartilage damage, which is suitable for professional athletes, body-building enthusiasts, people who love sports, women, the old and all outdoor body-building people.
Background
With the increase of age, the human body passes through the growth period and the maturation period and then enters the decline period, and the form, the structure and the function of the human body are continuously changed, which is the inevitable rule of metabolism. Osteoarthritis is almost inevitable for everyone, and in the affected joint, the cartilage covering and cushioning the ends of the bone gradually degrades, causing increased friction between the bones. The number of cells in the body of the middle-aged and the elderly people is in a descending trend along with the age, the number of the cells is reduced year by year, and the phenomena of muscle tissue weight reduction, muscle atrophy and the like are highlighted. The change of body components of the middle-aged and the elderly also shows on bones, the mineral substances and bone matrix of bone tissues are reduced, the bone density is reduced, the bone strength is reduced, and the osteoporosis and the osteoarthritis are easy to occur. In fact, although inflammation is one of the hallmarks of many arthritis, it is rare in osteoarthritis. Since the most important feature of osteoarthritis is pain in the joints, not inflammation.
Osteoarthritis is a common disease of middle-aged and elderly people due to joint pain and joint dysfunction (including joint deformity) caused by degeneration of articular cartilage. Osteoarthritis is a disease derived from cartilage, an elastic jelly tissue at the end of bone, which contains about 65% to 80% of water and has two main functions: reducing friction between bones; reducing repeated damage to bones in daily life.
For any population, the prevalence of osteoarthritis can reach 33% -66%. This data is not as accurate, but fairly speaking, osteoarthritis patients have approximately 2% of people under the age of 45, 30% of people between the ages of 45 and 64, and 63% -85% of people over the age of 65. The actual data may actually be even higher, since many people with osteoarthritis have not yet developed symptoms. Four major components of healthy cartilage: collagen, proteoglycan, chondrocytes and water, which work together to ensure smooth movement of the human body without causing pain. Therefore, the administration of some components for restoring the normal balance of cartilage matrix is of great significance in the prevention and onset of osteoarthritis.
Patent document CN 101961110 a discloses a method for preparing a functional food having effects of nourishing cartilage tissue and resisting arthritis. The anti-aging and anti-aging traditional Chinese medicine composition is prepared from the following raw materials in percentage by weight: 3-40%; 5-30% of Marasmius androsaceus extract, 5-40% of D-glucosamine hydrochloride, 0.1-10% of chondroitin sulfate and 1-15% of collagen.
Patent document CN 106135890 a discloses a nutritional composition suitable for patients with bone and joint diseases, which is prepared from 20-40% of marine fish oligopeptide, 10-30% of bone collagen peptide, 1-5% of organic calcium, 1-5% of casein phosphopeptide, 0.1-1% of saussurea involucrate culture, 1-5% of shark cartilage powder, 5-20% of inulin, 5-30% of oligosaccharide, 0.1-1% of vitamin, 1-3% of mineral and other raw materials.
The above prior art schemes only illustrate the effects of nourishing human cartilage tissue, diminishing inflammation and relieving pain, but chondrocytes not only synthesize collagen and proteoglycan required by cartilage, but also produce enzymes for decomposing aged collagen and proteoglycan. The health food composition of the present invention reduces the destructive effect of collagenase, elastase, hyaluronidase and the like on collagen, elastin, hyaluronic acid and the like by means of the significant inhibitory effect on these enzymes in addition to the nutritive cartilage and anti-inflammatory effect of the prior art, and simultaneously, since OPCs effectively inhibit inflammatory factors such as PG,5-HT, leukotriene and the like, and selectively bind to connective voxels of joints to relieve the symptoms of pain and edema.
Disclosure of Invention
According to an aspect of the present invention, it is an object of the present invention to provide a health food composition which can effectively prevent and treat articular cartilage damage, particularly, joint pain and joint dysfunction caused by degeneration of articular cartilage.
The health food composition according to the present invention comprises the following ingredients: ossein, hydrolyzed type II collagen, broccoli extract, and pine bark extract. The composition has effects of resisting inflammation, relieving pain and edema by increasing joint colloid and mucus, inhibiting cartilage protease, relieving cartilage injury, recombining damaged cartilage cell, promoting synthesis of new cartilage tissue and proteoglycan, and improving generation of hyaluronic acid in joint to form a thick, effective and lubricating protective pad.
Specifically, the composition comprises the following components in parts by weight: 1000 parts of ossein protein 200-1500 parts, 1500 parts of hydrolyzed type II collagen 200-1500 parts, 50-600 parts of broccoli extract and 50-650 parts of pine bark extract.
Preferably, the composition consists of the following components in parts by weight: 850 parts of collagen 250-1200 parts of hydrolyzed type II collagen 300-500 parts of broccoli extract and 60-650 parts of pine bark extract.
Preferably, the composition consists of the following components in parts by weight: 850 parts of collagen 300-.
Optionally, the composition further comprises 10-1000 parts of excipient, preferably 50-800 parts.
The unit of the above-mentioned parts by weight may be a unit by weight known in the field of medicines and foods, such as μ g, mg, g, kg, etc.
The excipient is one or more selected from starch, dextrin, pulvis Talci, sucrose powder, ethanol, microcrystalline cellulose, lactose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, magnesium stearate and silica gel micropowder. These excipients are all pharmaceutically acceptable excipients.
In the above composition:
the hydrolyzed type II collagen is a product prepared by taking chicken cartilage as a raw material through the processes of cleaning, enzymolysis, filtering, concentration, spray drying and the like, wherein the content of chondroitin sulfate is not less than 20% of the dry weight;
the broccoli extract is prepared by dehydrating, drying and crushing an edible part of fresh broccoli, and then extracting by ethanol, wherein the content of sulforaphane is not lower than 20mg/g in dry weight;
the pine bark extract is prepared by extracting pine bark as raw material with ethanol, and separating, wherein the content of procyanidine (OPCs) is not less than 60% of dry weight.
The dosage form of the composition comprises: tablets, pills, capsules, granules and the like.
The composition can be prepared by adopting a conventional method in the technical field, namely weighing the raw materials, namely the bone collagen, the hydrolyzed type II collagen, the broccoli extract and the pine bark extract according to the weight ratio, sieving and uniformly mixing for later use; then adding excipient, and preparing into any clinically acceptable dosage form according to conventional method in the field.
Has the advantages that:
the health food composition for preventing and treating articular cartilage damage, provided by the invention, is prepared by compounding collagen, hydrolyzed type II collagen, a broccoli extract and a pine bark extract according to a specific proportion, wherein the collagen can increase the colloid and mucus of joints and accelerate the repair and survival of cartilage tissues and joint fluid; the hydrolyzed type II collagen contains abundant hyaluronic acid and chondroitin sulfate, is helpful for resisting cartilage protease, recombining damaged cartilage cells, promoting the synthesis of new cartilage tissues and proteoglycan, improving the generation of hyaluronic acid in joints, forming a thick, effective and lubricating protective pad for protecting and lubricating joint joints, and has strong anti-inflammatory and analgesic effects; sulforaphane in broccoli extract slows down the progression of cartilage damage by preventing the action of various enzymes that cause joint degeneration in osteoarthritis; the pine bark extract contains rich procyanidin, which has obvious inhibition effect on collagenase, elastase, hyaluronidase and the like, thereby reducing the damage effect of the enzymes on collagen, elastin, hyaluronic acid and the like, and the OPCs effectively inhibit inflammatory factors such as PG,5-HT, leukotrienes and the like and selectively combine with connective voxels of joints to relieve the symptoms of pain, edema and the like.
Detailed Description
Hereinafter, the present invention will be described in detail. Before the description is made, it should be understood that the terms used in the present specification and the appended claims should not be construed as limited to general and dictionary meanings, but interpreted based on the meanings and concepts corresponding to technical aspects of the present invention on the basis of the principle that the inventor is allowed to define terms appropriately for the best explanation. Accordingly, the description proposed herein is just a preferable example for the purpose of illustrations only, not intended to limit the scope of the invention, so it should be understood that other equivalents and modifications could be made thereto without departing from the spirit and scope of the invention.
The following examples are given by way of illustration of embodiments of the invention and are not to be construed as limiting the invention, and it will be understood by those skilled in the art that modifications may be made without departing from the spirit and scope of the invention. Unless otherwise specified, reagents and equipment used in the following examples are commercially available products.
Example 1:
selecting raw materials of bone collagen, hydrolyzed type II collagen, broccoli extract and pine bark extract, respectively sieving, and taking materials with a 40-mesh sieve to prepare the preparation.
Respectively weighing the screened raw materials: 1000g of ossein, 250g of hydrolyzed type II collagen, 300g of broccoli extract, 60g of pine bark extract and 20g of magnesium stearate are fully and uniformly stirred, poured into a capsule filling mold, filled into capsules, polished and subpackaged to prepare 3000 capsules.
Example 2:
selecting raw materials of bone collagen, hydrolyzed type II collagen, broccoli extract and pine bark extract, respectively sieving, and taking materials with a 80-mesh sieve to prepare the preparation.
Respectively weighing the screened raw materials: 250g of ossein, 1500g of hydrolyzed type II collagen, 60g of broccoli extract, 650g of pine bark extract and 100g of sucrose powder, fully and uniformly stirring, using 0.8 percent (wt%) of sodium carboxymethyl cellulose aqueous solution as an adhesive to prepare a soft material, putting the soft material into a pill making machine to make pills, drying, finishing pills and subpackaging to prepare 4000 pills.
Example 3:
selecting raw materials of bone collagen, hydrolyzed type II collagen, broccoli extract and pine bark extract, respectively sieving, and taking materials with a 80-mesh sieve to prepare the preparation.
Respectively weighing the screened raw materials: 850g of ossein, 350g of hydrolyzed type II collagen, 500g of broccoli extract, 450g of pine bark extract, 550g of lactose and 200g of microcrystalline cellulose, fully and uniformly stirring, using 50% (vol%) ethanol as an adhesive to prepare a soft material, preparing the soft material into granules by a swing granulator with a 14-mesh screen, putting the granules into a multifunctional boiling dryer, boiling and drying for about 40min at 50 ℃, controlling the water content of the granules to be 3 wt% -5 wt%, carrying out granule finishing, adding magnesium stearate and aerosil which are 0.5% of the total weight of raw materials into the granules, totally mixing, tabletting, coating with a film, and subpackaging to obtain 3700 tablets.
Example 4:
selecting raw materials of bone collagen, hydrolyzed type II collagen, broccoli extract and pine bark extract, respectively sieving, and taking materials with a 80-mesh sieve to prepare the preparation.
Respectively weighing the screened raw materials: 300g of ossein, 1200g of hydrolyzed type II collagen, 80g of broccoli extract, 300g of pine bark extract and 600g of sucrose powder, fully and uniformly stirring, using 50% (vol%) ethanol as an adhesive to prepare a soft material, granulating by a swing granulator with a 14-mesh screen, placing the granules in a multifunctional boiling dryer, boiling and drying at 50 ℃ for about 40min, controlling the water content of the granules to be 3-5 wt%, then finishing the granules, and subpackaging to prepare 600 bags of granules.
Example 5:
except that the raw materials comprise: 3300 tablets were prepared in substantially the same manner as in example 3, except that 550g of collagen, 1000g of hydrolyzed type II collagen, 350g of broccoli extract, 180g of pine bark extract, 570g of lactose, and 20g of magnesium stearate were used.
Experimental examples
1. Subject and method
1.1 test subjects
All the subjects in the experiment are the population with damaged soft tissue of the knee joint, 23 males and 19 females in 42 subjects, the age is 18-55, and the average age (37.3 +/-5.8) is year old.
1.2 Experimental methods
Grouping: 42 subjects were randomly divided into 3 groups, control group (N-14), experimental group a (N-14), and experimental group B (N-14). The control group was administered placebo for 3 tablets/day for 8 weeks; experimental group a was administered a tablet of the composition of the present invention (example 3) 3 tablets/day for 8 weeks; experimental group B was administered a tablet of the composition of the present invention (example 5) 3 tablets/day for 8 weeks. Throughout the duration of the experiment, the subjects were not used, including topical or oral administration of other drugs or foods that help to improve joint symptoms.
1.3 main observation indexes: and (4) adopting Lequesne index scoring standard to improve the dysfunction.
1.3.1 Knee joint rest pain
Normally 0 point; mild, no influence on work as 1 point; heavier, no influence on sleep is 2 points; the serious and affecting sleep is divided into 3 points.
1.3.2 Knee-joint movement pain
Normally 0 point; pain in upstairs and downstairs (on slopes), and no influence on flexion and extension is 1 point; pain in upstairs and downstairs (on slopes) and squatting is 2 points; pain was divided into 3 points when walking.
1.3.3 tenderness
Normally 0 point; pain was 1 point at heavy stress; moderate pressure pain was scored 2; the pain due to light pressure was divided into 3 points.
1.3.4 swelling
Normally 0 point; slightly swollen and clear knee and eye are 1 point; soft tissue swelling, unclear knee and eye are 2 points; the unclear knee and eye is divided into 3 points.
1.3.5 morning stiffness
Normally 0 point; stiff flexion and extension but rapid recovery (<10min) of 1 point; the stiffness and short-term recovery (10-30 min) are 2 minutes; stiffness, recovery (>30min) for a longer time was 3 min.
1.3.6 Walking ability
Is not limited to 0 min; walking over 1km, but limited to 1 minute; walking for about 1km or 15min is 2 min; walking for 3 minutes at 500-900 m or 8-15 min; walking for 300-500 m is 4 minutes; walking for 5 minutes at 100-300 m; walking less than 100m is 6 minutes; adding 1 point to a single crutch; double crutches plus 2 points were used.
1.4 statistics of data
The resulting data were processed with Excel, statistical analysis of the test data was performed using single blind and t-test, expressed as mean ± SD (mean ± standard deviation), with P > 0.05 considered no significant difference, P <0.05 considered significant difference, and P < 0.01 considered very significant difference.
2 results and analysis of the experiments
2.1 Lequesne index score results
TABLE 1 results of Lequesne index scoring of subjects before and after the experiment
Significant difference before and after administration (p <0.05)
As can be seen from table 1, the Lequesne index score decreased after the experiment of the control group and the experiment group a compared with that before the experiment, and the Lequesne index score decreased before and after the experiment of the experiment group B with significant difference (p < 0.05).
3. Conclusion
Therefore, the product of the composition has stronger functions than the common joint protection product, and particularly, the product of the composition can obviously improve the functional disorder caused by the damage of the articular cartilage.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (6)
1. A health food composition comprises the following active ingredients: 550 parts of bone collagen, 1000 parts of hydrolyzed type II collagen, 350 parts of broccoli extract and 180 parts of pine bark extract.
2. A nutraceutical composition according to claim 1, wherein the composition further comprises optionally 10-1000 parts of excipients.
3. A nutraceutical composition according to claim 2, optionally further comprising 50-800 parts of excipients.
4. A health food composition according to claim 2 or 3, wherein the excipient is one or more selected from starch, dextrin, talc, sucrose powder, ethanol, microcrystalline cellulose, lactose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, magnesium stearate and aerosil.
5. The health food composition according to claim 1, wherein in the composition:
the hydrolyzed type II collagen is a product prepared by taking chicken cartilage as a raw material through the processes of cleaning, enzymolysis, filtering, concentration and spray drying, wherein the content of chondroitin sulfate is not less than 20 percent of the dry weight;
the broccoli extract is prepared by dehydrating, drying and crushing an edible part of fresh broccoli, and extracting by ethanol, wherein the content of sulforaphane is not less than 20mg/g of dry weight;
the pine bark extract is prepared by extracting pine bark serving as a raw material with ethanol and separating, wherein the content of procyanidine is not less than 60% of the dry weight.
6. The health food composition according to claim 1, wherein the composition is in a dosage form comprising: tablet, pill, capsule, and granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711365869.6A CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711365869.6A CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108112997A CN108112997A (en) | 2018-06-05 |
| CN108112997B true CN108112997B (en) | 2021-02-26 |
Family
ID=62229366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711365869.6A Active CN108112997B (en) | 2017-12-18 | 2017-12-18 | A health food composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108112997B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108968077A (en) * | 2018-07-13 | 2018-12-11 | 杭州相生相成科技有限公司 | A kind of elastin laminin Gly-His-Lys and preparation method thereof |
| CN111467481A (en) * | 2020-05-08 | 2020-07-31 | 江苏新中基生物科技有限公司 | Composition for improving and/or preventing osteoarthritis and application thereof |
| CN111820348A (en) * | 2020-06-02 | 2020-10-27 | 大连普瑞康生物技术有限公司 | Saussurea involucrata culture ossein peptide composite fruit juice and preparation method thereof |
| CN116784480A (en) * | 2023-06-07 | 2023-09-22 | 北京康比特体育科技股份有限公司 | Composition containing hydrolyzed collagen II and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| JP2003325136A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Arthritis-improving food |
| TW200744577A (en) * | 2005-07-13 | 2007-12-16 | Horphag Res Luxembourg Holding Sa | Method for treating osteoarthritis |
| CN101983722A (en) * | 2010-10-20 | 2011-03-09 | 北京康比特体育科技股份有限公司 | Composition for preventing and treating joint soft tissue injury and complications thereof |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6780841B2 (en) * | 2001-11-13 | 2004-08-24 | Biocell Technology, Llc | Hyaluronic acid and chondroitin sulfate based hydrolyzed collagen type II and method of making same |
| US20040086581A1 (en) * | 2002-11-06 | 2004-05-06 | Jones Edwin B. | Bio-energetic joint and arthritis pain formula |
-
2017
- 2017-12-18 CN CN201711365869.6A patent/CN108112997B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6333304B1 (en) * | 1999-04-20 | 2001-12-25 | Teresa K. Bath | Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue |
| JP2003325136A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Arthritis-improving food |
| TW200744577A (en) * | 2005-07-13 | 2007-12-16 | Horphag Res Luxembourg Holding Sa | Method for treating osteoarthritis |
| CN101983722A (en) * | 2010-10-20 | 2011-03-09 | 北京康比特体育科技股份有限公司 | Composition for preventing and treating joint soft tissue injury and complications thereof |
| CN105725190A (en) * | 2016-02-15 | 2016-07-06 | 北京东方兴企食品工业技术有限公司 | Functional nutrient food for improving joints |
Non-Patent Citations (1)
| Title |
|---|
| 吃西兰花或有助预防关节炎;佚名;《蔬菜》;20131231;第70页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108112997A (en) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108112997B (en) | A health food composition | |
| CN103082276B (en) | Composition for reducing sport injury and promoting sport injury repair | |
| CN102698254B (en) | Composition for increasing bone mineral density, preparation agent containing same, and preparation method of same | |
| CN101983722B (en) | Composition for preventing and treating joint soft tissue injury and complications thereof | |
| EP3096767B1 (en) | Composition comprising okra for use in reducing dietary fat absorption | |
| CN104758360B (en) | It is a kind of to increase the composition of bone density | |
| CN102626225B (en) | Health food having functions of bone density increasing and joint protecting, and preparation method thereof | |
| CN106729599A (en) | A kind of pharmaceutical composition for increasing bone density and its production and use | |
| CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
| CN104116022B (en) | Composite health food for improving women climacteric syndrome and preparation method thereof | |
| CN109480213A (en) | A kind of sport nutrition matched combined object with joint maintenance and maintenance | |
| CN108741099A (en) | One kind contributing to comfortable alimentation composition in joint and its preparation method and application | |
| CN111000973A (en) | Composition with gout improving effect and application thereof | |
| CN106262809A (en) | A kind of bone density that strengthens alleviates the compositions of person in middle and old age's arthralgia | |
| CN107252099A (en) | A kind of health food for improving osteoarthritic inflammation and preparation method thereof | |
| CN110897159A (en) | A composition for preventing or treating joint diseases | |
| WO2018107324A1 (en) | Calcium supplement composition for decreasing risk of hypercalcemia and use thereof | |
| CN106177908A (en) | A kind of have compositions increasing bone substance density improving function and preparation method thereof | |
| CN104721805A (en) | Granules for alleviating and preventing joint diseases and preparation method thereof | |
| CN107668724A (en) | A kind of compound preparation of ammonia sugar chondroitin collagen turmeric and preparation method thereof | |
| CN104523804B (en) | A kind of capsule for increasing bone density and preparation method thereof | |
| KR20050101143A (en) | Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin | |
| WO2014016238A1 (en) | Compositions for oral administration having a beneficial effect on tendinopathies and ligament injuries | |
| CN105831738A (en) | Polypeptide glucosamine chondroitin nutritional health food | |
| CN110935004A (en) | Composition for treating shoulder and neck diseases and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |